Osmotic Demyelination Syndrome Resulting from an Unexpected Response to Tolvaptan in a Patient with Heart Failure / 대한내과학회지
Korean Journal of Medicine
; : 62-65, 2017.
Article
en Ko
| WPRIM
| ID: wpr-194638
Biblioteca responsable:
WPRO
ABSTRACT
Hyponatremia is commonly encountered in patients with heart failure and has a poor prognosis. Tolvaptan, a novel selective vasopressin V2 receptor blocker, has received attention as an effective drug for treating the syndrome of inappropriate antidiuretic hormone secretion and hypervolemic hyponatremia. However, the safety of tolvaptan in the treatment of hyponatremia is not clear. We experienced a 78-year-old woman with a history of heart failure, atrial fibrillation, and hyponatremia who developed osmotic demyelination syndrome as an unexpected response to treatment with tolvaptan.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Pronóstico
/
Fibrilación Atrial
/
Enfermedades Desmielinizantes
/
Receptores de Vasopresinas
/
Corazón
/
Insuficiencia Cardíaca
/
Hiponatremia
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
Idioma:
Ko
Revista:
Korean Journal of Medicine
Año:
2017
Tipo del documento:
Article